Emergency Medicine

Episodes 1-16 of 25

• 

  RestartResume

  Cracking the CRS Code in Myeloma: Insights from a Comprehensive Case Review

  RestartResume

  Cracking the CRS Code in Myeloma: Insights from a Comprehensive Case Review

  CME/CE

  Cracking the CRS Code in Myeloma: Insights from a Comprehensive Case Review

  0.25 credits

  • 

    

    Caitlin Costello, MD

  • 

    

    Sagar Lonial, MD, FACP

  0.25 credits

• 

  RestartResume

  A Roadmap to Safe and Effective Bispecific Antibody Use in Myeloma: Mitigating and Managing Adverse Events

  RestartResume

  A Roadmap to Safe and Effective Bispecific Antibody Use in Myeloma: Mitigating and Managing Adverse Events

  CME/CE

  A Roadmap to Safe and Effective Bispecific Antibody Use in Myeloma: Mitigating and Managing Adverse Events

  0.25 credits

  • 

    

    Caitlin Costello, MD

  • 

    

    Sagar Lonial, MD, FACP

  0.25 credits

• 

  RestartResume

  Approved Bispecific Antibodies for RRMM: Review of the Pivotal Trials   

  RestartResume

  Approved Bispecific Antibodies for RRMM: Review of the Pivotal Trials   

  MinuteCE®

  Approved Bispecific Antibodies for RRMM: Review of the Pivotal Trials   

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  • 

    

    Caitlin Costello, MD

  1.00 program credit

• 

  MinuteCE®

  Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma 

  1.00 credit 10 episodes

  • 

    

    Sagar Lonial, MD, FACP

  • 

    

    Caitlin Costello, MD

  1.00 credit 10 episodes

• 

  RestartResume

  Preventing CRS and Neurotoxicities Related to Bispecific Antibodies

  RestartResume

  Preventing CRS and Neurotoxicities Related to Bispecific Antibodies

  MinuteCE®

  Preventing CRS and Neurotoxicities Related to Bispecific Antibodies

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  • 

    

    Caitlin Costello, MD

  1.00 program credit

• 

  RestartResume

  Efficacy Data for Bispecific Antibodies in RRMM

  RestartResume

  Efficacy Data for Bispecific Antibodies in RRMM

  MinuteCE®

  Efficacy Data for Bispecific Antibodies in RRMM

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  1.00 program credit

• 

  RestartResume

  Considerations for Dosing Bispecific Antibodies

  RestartResume

  Considerations for Dosing Bispecific Antibodies

  MinuteCE®

  Considerations for Dosing Bispecific Antibodies

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  • 

    

    Caitlin Costello, MD

  1.00 program credit

• 

  RestartResume

  Clinical Challenges With Triple-Class or Penta-Refractory MM

  RestartResume

  Clinical Challenges With Triple-Class or Penta-Refractory MM

  MinuteCE®

  Clinical Challenges With Triple-Class or Penta-Refractory MM

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  • 

    

    Caitlin Costello, MD

  1.00 program credit

• 

  RestartResume

  Integrating Bispecific Antibodies Into Clinical Practice

  RestartResume

  Integrating Bispecific Antibodies Into Clinical Practice

  MinuteCE®

  Integrating Bispecific Antibodies Into Clinical Practice

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  • 

    

    Caitlin Costello, MD

  1.00 program credit

• 

  RestartResume

  Bispecific Antibodies: The Newest Immunotherapy on the Block for RRMM

  RestartResume

  Bispecific Antibodies: The Newest Immunotherapy on the Block for RRMM

  MinuteCE®

  Bispecific Antibodies: The Newest Immunotherapy on the Block for RRMM

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  • 

    

    Caitlin Costello, MD

  1.00 program credit

• 

  RestartResume

  Managing Infections, Cytopenias, and Other AEs Related to Bispecific Antibodies

  RestartResume

  Managing Infections, Cytopenias, and Other AEs Related to Bispecific Antibodies

  MinuteCE®

  Managing Infections, Cytopenias, and Other AEs Related to Bispecific Antibodies

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  • 

    

    Caitlin Costello, MD

  1.00 program credit

• 

  RestartResume

  Step-Up Dosing of Bispecific Antibodies: The Need for Hospitalization

  RestartResume

  Step-Up Dosing of Bispecific Antibodies: The Need for Hospitalization

  MinuteCE®

  Step-Up Dosing of Bispecific Antibodies: The Need for Hospitalization

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  • 

    

    Caitlin Costello, MD

  1.00 program credit

• 

  RestartResume

  The Evolving Treatment Paradigm for RRMM: The Role of Bispecific Antibodies   

  RestartResume

  The Evolving Treatment Paradigm for RRMM: The Role of Bispecific Antibodies   

  MinuteCE®

  The Evolving Treatment Paradigm for RRMM: The Role of Bispecific Antibodies   

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  • 

    

    Caitlin Costello, MD

  1.00 program credit

• 

  RestartResume

  Expanding Screening, Improving Treatment Acceptance, and Optimizing Outcomes for Patients with Moderate to Severe Alcohol Use Disorder (AUD)

  RestartResume

  Expanding Screening, Improving Treatment Acceptance, and Optimizing Outcomes for Patients with Moderate to Severe Alcohol Use Disorder (AUD)

  CME/CE

  Expanding Screening, Improving Treatment Acceptance, and Optimizing Outcomes for Patients with Moderate to Severe Alcohol Use Disorder (AUD)

  0.50 credits

  • 

    

    Annie Levesque, MD, MSc

  • 

    

    Ethan A. Cowan, MD

  0.50 credits

• 

  RestartResume

  Selecting an AUD Treatment: Disulfiram

  RestartResume

  Selecting an AUD Treatment: Disulfiram

  MinuteCE®

  Selecting an AUD Treatment: Disulfiram

  • 

    

    Edwin A. Salsitz, MD, DFASAM

  • 

    

    Ethan A. Cowan, MD

• 

  RestartResume

  Selecting an AUD Treatment: Off-Label Agents

  RestartResume

  Selecting an AUD Treatment: Off-Label Agents

  MinuteCE®

  Selecting an AUD Treatment: Off-Label Agents

  • 

    

    Ethan A. Cowan, MD

  • 

    

    Edwin A. Salsitz, MD, DFASAM

• Prev
• 1
• 2
• Next